Perfecta T-cell tumoribus, ut non-T-cell Hodgkin lymphoma, et aliorum valde medicamento repugnant incursio; et aegris habent plerumque pauperes deploratae. Nuper, "rerum natura" duorum articulorum series published in pathogenesis de nova interpretatione non-T-Hodgkin scriptor cell lymphoma, ita nec sine novam directionem de progressionem effective therapies pro novis quaestionibus huius generis aspersos maculis lymphoma.
In the first study, the Wartewig team used the fusion protein ITK-SYK to construct a transgenic mouse model of late-onset T-cell lymphoma (Nature. Doi: 10.1038 / nature24649), and found that the single or double copy of the PDCD1 gene encoding the PD1 protein was deleted. T cell lymphoma undergoes rapid malignant transformation and accelerates the death of the mouse model. In addition, the application of PD1 or PD-L1 inhibitors can produce similar effects. The related mechanism is that PD1 up-regulates PTEN expression and inhibits the tumor malignant proliferation pathway PI3K.
In another article, Maciocia et al. Applied chimeric antigen receptor T cell immunotherapy (CAR-T) therapy (Nat Med. Doi: 10.1038 / nm.4444) to construct CAR-T cells that specifically target TRBC1 but not TRBC2 To treat TRBC1-positive T-cell carcinoma. While killing tumor cells, leaving enough T cells to fight infection. The clinical trial of this method will be officially launched in 2018.
Megan senior editor naturam, ut supra dictum Cully praedictis amet curatio nova inventa belli providebit treatment pro octavo decimo T-cell malignancies et monemus ut huiusmodi similitudines anorum sunt non apta curatio cum PD1 inhibitors aut PDL1.
